Haleon plc (LON:HLN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Haleon plc (LON:HLN) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is GBX 398.67.

HLN has been the topic of several research reports. Jefferies Financial Group lowered their target price on Haleon from GBX 450 to GBX 400 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a research note on Thursday, April 30th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a GBX 512 price objective on shares of Haleon in a research note on Thursday, April 30th.

Insider Buying and Selling at Haleon

In other news, insider Brian McNamara sold 63,012 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of GBX 368, for a total value of £231,884.16. Company insiders own 0.01% of the company’s stock.

Haleon Price Performance

Haleon stock opened at GBX 344 on Wednesday. The business has a 50 day simple moving average of GBX 354.93 and a 200-day simple moving average of GBX 369.35. The stock has a market capitalization of £30.58 billion, a PE ratio of 18.59, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25. The company has a debt-to-equity ratio of 52.26, a current ratio of 0.92 and a quick ratio of 0.93. Haleon has a 12 month low of GBX 325 and a 12 month high of GBX 419.50.

Haleon (LON:HLN) last released its quarterly earnings data on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.43% and a net margin of 12.59%. Equities analysts predict that Haleon will post 19.5033282 earnings per share for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.